U.S. markets open in 6 hours 2 minutes
  • S&P Futures

    4,171.50
    -4.75 (-0.11%)
     
  • Dow Futures

    34,005.00
    -76.00 (-0.22%)
     
  • Nasdaq Futures

    14,039.25
    +9.75 (+0.07%)
     
  • Russell 2000 Futures

    2,250.40
    -8.60 (-0.38%)
     
  • Crude Oil

    62.84
    -0.29 (-0.46%)
     
  • Gold

    1,780.20
    0.00 (0.00%)
     
  • Silver

    25.92
    -0.18 (-0.69%)
     
  • EUR/USD

    1.1985
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5730
    0.0000 (0.00%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3850
    +0.0010 (+0.07%)
     
  • USD/JPY

    108.4700
    -0.3130 (-0.29%)
     
  • BTC-USD

    57,131.81
    -291.49 (-0.51%)
     
  • CMC Crypto 200

    1,300.30
    -91.41 (-6.57%)
     
  • FTSE 100

    7,027.58
    +8.05 (+0.11%)
     
  • Nikkei 225

    29,685.37
    +2.00 (+0.01%)
     

Recap: Fulgent Genetics Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Fulgent Genetics (NASDAQ:FLGT) moved higher by 24.0% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 15400.00% year over year to $6.20, which beat the estimate of $4.05.

Revenue of $294,978,000 rose by 3417.09% year over year, which beat the estimate of $199,440,000.

Guidance

Fulgent Genetics Sees FY21 EPS ~$12.50 Vs. $11.55 Est., Sales ~$800M Vs. $600.24M Est.

Details Of The Call

Date: Mar 04, 2021

Time: 04:30 PM

View more earnings on FLGT

ET Webcast URL: https://edge.media-server.com/mmc/p/jf6vsajc

Technicals

52-week high: $189.89

52-week low: $6.70

Price action over last quarter: Up 246.36%

Company Profile

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to a disease and enhanced disease treatment and prognosis.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.